These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 10359174)

  • 1. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma?
    Blakely ML; Lobe TE; Anderson JR; Donaldson SS; Andrassy RJ; Parham DM; Wharam MD; Qualman SJ; Wiener ES; Grier HE; Crist WM
    J Pediatr Surg; 1999 May; 34(5):736-41; discussion 741-2. PubMed ID: 10359174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997.
    Raney RB; Stoner JA; Walterhouse DO; Andrassy RJ; Donaldson SS; Laurie F; Meyer WH; Qualman SJ; Crist WM;
    Pediatr Blood Cancer; 2004 Jun; 42(7):618-25. PubMed ID: 15127417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
    Wolden SL; Lyden ER; Arndt CA; Hawkins DS; Anderson JR; Rodeberg DA; Morris CD; Donaldson SS
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1071-6. PubMed ID: 26581144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
    Crist WM; Anderson JR; Meza JL; Fryer C; Raney RB; Ruymann FB; Breneman J; Qualman SJ; Wiener E; Wharam M; Lobe T; Webber B; Maurer HM; Donaldson SS
    J Clin Oncol; 2001 Jun; 19(12):3091-102. PubMed ID: 11408506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Raney RB; Walterhouse DO; Meza JL; Andrassy RJ; Breneman JC; Crist WM; Maurer HM; Meyer WH; Parham DM; Anderson JR
    J Clin Oncol; 2011 Apr; 29(10):1312-8. PubMed ID: 21357783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
    Baker KS; Anderson JR; Link MP; Grier HE; Qualman SJ; Maurer HM; Breneman JC; Wiener ES; Crist WM
    J Clin Oncol; 2000 Jun; 18(12):2427-34. PubMed ID: 10856103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?
    Wiener ES; Anderson JR; Ojimba JI; Lobe TE; Paidas C; Andrassy RJ; Raney RB; Qualman SJ; Donaldson SS; Maurer HM; Link MP; Crist WM; Grier HE
    Semin Pediatr Surg; 2001 Aug; 10(3):146-52. PubMed ID: 11481652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?
    Arndt CA; Donaldson SS; Anderson JR; Andrassy RJ; Laurie F; Link MP; Raney RB; Maurer HM; Crist WM
    Cancer; 2001 Jun; 91(12):2454-68. PubMed ID: 11413538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What comprises appropriate therapy for children/adolescents with rhabdomyosarcoma arising in the abdominal wall? A report from the Intergroup Rhabdomyosarcoma Study Group.
    Beech TR; Moss RL; Anderson JA; Maurer HM; Qualman SJ; Breneman JC; Wiener ES; Crist WM
    J Pediatr Surg; 1999 May; 34(5):668-71. PubMed ID: 10359160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL; Anderson J; Pappo AS; Meyer WH;
    J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III.
    Wolden SL; Anderson JR; Crist WM; Breneman JC; Wharam MD; Wiener ES; Qualman SJ; Donaldson SS
    J Clin Oncol; 1999 Nov; 17(11):3468-75. PubMed ID: 10550144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.
    Chen C; Shu HK; Goldwein JW; Womer RB; Maity A
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1294-9. PubMed ID: 12654440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhabdomyosarcoma in children: a SEER population based study.
    Perez EA; Kassira N; Cheung MC; Koniaris LG; Neville HL; Sola JE
    J Surg Res; 2011 Oct; 170(2):e243-51. PubMed ID: 21529833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997.
    Raney RB; Chintagumpala M; Anderson J; Pappo A; Qualman S; Wharam M; Wiener E; Meyer W;
    Pediatr Blood Cancer; 2008 May; 50(5):958-64. PubMed ID: 18240175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.
    Smith LM; Anderson JR; Qualman SJ; Crist WM; Paidas CN; Teot LA; Pappo AS; Link MP; Grier HE; Wiener ES; Breneman JC; Raney RB; Maurer HM; Donaldson SS
    J Clin Oncol; 2001 Oct; 19(20):4058-64. PubMed ID: 11600608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG.
    Donaldson SS; Meza J; Breneman JC; Crist WM; Laurie F; Qualman SJ; Wharam M;
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):718-28. PubMed ID: 11597814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcome for patients with middle ear rhabdomyosarcoma: a children's oncology group study.
    Hawkins DS; Anderson JR; Paidas CN; Wharam MD; Qualman SJ; Pappo AS; Scott Baker K; Crist WM
    J Clin Oncol; 2001 Jun; 19(12):3073-9. PubMed ID: 11408504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997.
    Blakely ML; Andrassy RJ; Raney RB; Anderson JR; Wiener ES; Rodeberg DA; Paidas CN; Lobe TE; Crist WM;
    J Pediatr Surg; 2003 Mar; 38(3):347-53. PubMed ID: 12632347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Third Intergroup Rhabdomyosarcoma Study.
    Crist W; Gehan EA; Ragab AH; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J; Heyn R
    J Clin Oncol; 1995 Mar; 13(3):610-30. PubMed ID: 7884423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.